Cancer Therapy : Preclinical SST 0001 , a Chemically Modified Heparin , Inhibits Myeloma Growth and Angiogenesis via Disruption of the Heparanase / Syndecan-1 Axis
暂无分享,去创建一个
F. Zunino | R. Sanderson | C. Pisano | G. Torri | Yongsheng Ren | Yang Yang | I. Vlodavsky | B. Casu | S. Penco | P. Carminati | Vishnu C. Ramani | A. Naggi | M. Tortoreto | J. Ritchie | V. Ramani | B. Casu*
[1] F. Zunino,et al. Pre-clinical and clinical significance of heparanase in Ewing’s sarcoma , 2011, Journal of cellular and molecular medicine.
[2] L. Kiesel,et al. Faculty Opinions recommendation of Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. , 2011 .
[3] R. Sanderson,et al. Heparanase Plays a Dual Role in Driving Hepatocyte Growth Factor (HGF) Signaling by Enhancing HGF Expression and Activity*♦ , 2010, The Journal of Biological Chemistry.
[4] R. Sanderson,et al. Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis , 2010, The FEBS journal.
[5] N. Pavlakis,et al. Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] A. Purushothaman,et al. Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. , 2010, Blood.
[7] J. Laubach,et al. The evolution and impact of therapy in multiple myeloma , 2010, Medical oncology.
[8] R. Reijmers,et al. Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma. , 2009, Blood.
[9] Y. Khotskaya,et al. Syndecan-1 Is Required for Robust Growth, Vascularization, and Metastasis of Myeloma Tumors in Vivo* , 2009, The Journal of Biological Chemistry.
[10] S. Lonial,et al. Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma , 2009, British journal of haematology.
[11] K. Anderson,et al. Preclinical Studies in Support of Defibrotide for the Treatment of Multiple Myeloma and Other Neoplasias , 2009, Clinical Cancer Research.
[12] A. Purushothaman,et al. Heparanase Stimulation of Protease Expression Implicates It as a Master Regulator of the Aggressive Tumor Phenotype in Myeloma* , 2008, Journal of Biological Chemistry.
[13] D. Dingli,et al. Improved survival in multiple myeloma and the impact of novel therapies. , 2008, Blood.
[14] L. Borsig,et al. P‐selectin‐ and heparanase‐dependent antimetastatic activity of non‐anticoagulant heparins , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[15] B. Barlogie,et al. Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients , 2007, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[16] B. Barlogie,et al. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. , 2007, Blood.
[17] R. Sanderson,et al. Non-Anticoagulant Heparins and Inhibition of Cancer , 2007, Pathophysiology of Haemostasis and Thrombosis.
[18] F. Zhan,et al. Heparanase Enhances Syndecan-1 Shedding , 2007, Journal of Biological Chemistry.
[19] E. Mckenzie,et al. Heparanase: a target for drug discovery in cancer and inflammation , 2007, British journal of pharmacology.
[20] Kenneth C Anderson,et al. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. , 2007, Experimental hematology.
[21] M. Rodger,et al. The effect of low‐molecular‐weight heparin on cancer survival. A systematic review and meta‐analysis of randomized trials , 2007, Journal of thrombosis and haemostasis : JTH.
[22] P. Raynaud,et al. Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. , 2006, Blood.
[23] Christian Jakob,et al. Angiogenesis in multiple myeloma. , 2006, European journal of cancer.
[24] Levon M Khachigian,et al. Phosphomannopentaose sulfate (PI-88): heparan sulfate mimetic with clinical potential in multiple vascular pathologies. , 2006, Cardiovascular drug reviews.
[25] I. Vlodavsky,et al. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. , 2006, Cancer research.
[26] R. Sanderson,et al. Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: Growth regulation and the prospect of new cancer therapies , 2005, Journal of cellular biochemistry.
[27] Vito Ferro,et al. Synthesis, biological activity, and preliminary pharmacokinetic evaluation of analogues of a phosphosulfomannan angiogenesis inhibitor (PI-88). , 2005, Journal of medicinal chemistry.
[28] G. Giannini,et al. Modulation of the Heparanase-inhibiting Activity of Heparin through Selective Desulfation, Graded N-Acetylation, and Glycol Splitting* , 2005, Journal of Biological Chemistry.
[29] K. Podar,et al. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. , 2005, Blood.
[30] F. B. Sørensen,et al. Syndecan‐1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival , 2005, British journal of haematology.
[31] L. Suva,et al. Heparan sulfate proteoglycans and heparanase--partners in osteolytic tumor growth and metastasis. , 2004, Matrix biology : journal of the International Society for Matrix Biology.
[32] F. Zhan,et al. High heparanase activity in multiple myeloma is associated with elevated microvessel density. , 2003, Cancer research.
[33] G. Taraboletti,et al. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. , 2003, Cancer research.
[34] G. Pruneri,et al. Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients , 2002, British journal of haematology.
[35] Benito Casu,et al. Short heparin sequences spaced by glycol-split uronate residues are antagonists of fibroblast growth factor 2 and angiogenesis inhibitors. , 2002, Biochemistry.
[36] J. Epstein,et al. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. , 2002, Blood.
[37] M. V. van Oers,et al. Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. , 2002, Blood.
[38] Dianjun Cao,et al. High levels of soluble syndecan-1 in myeloma-derived bone marrow : modulation of hepatocyte growth factor activity , 2000 .
[39] J. Epstein,et al. Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. , 2000, Blood.
[40] I. Vlodavsky. Preparation of Extracellular Matrices Produced by Cultured Corneal Endothelial and PF‐HR9 Endodermal Cells , 1999, Current protocols in cell biology.
[41] Masato Kato,et al. Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2 , 1998, Nature Medicine.
[42] A. Waage,et al. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. , 1998, Blood.
[43] D. Bergsagel. The incidence and epidemiology of plasma cell neoplasms. , 1995, Stem cells.
[44] J. Woodliff,et al. Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen , 1993 .
[45] A. Lander,et al. Adhesion of B lymphoid (MPC-11) cells to type I collagen is mediated by integral membrane proteoglycan, syndecan. , 1992, Journal of immunology.
[46] I. Cohen,et al. Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species. , 1987, Blood.
[47] Z. Fuks,et al. Lymphoma cell-mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: relationship to tumor cell metastasis. , 1983, Cancer research.
[48] R. Sanderson,et al. Syndecan-1: a dynamic regulator of the myeloma microenvironment , 2007, Clinical & Experimental Metastasis.
[49] A. Sundan,et al. The role of hepatocyte growth factor and its receptor c-Met in multiple myeloma and other blood malignancies. , 1999, Leukemia & lymphoma.
[50] B. Barlogie,et al. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. , 1998, Blood.
[51] T. Peretz,et al. Inhibition of tumor metastasis by heparanase inhibiting species of heparin. , 1994, Invasion & metastasis.